BofA moves to No Rating on Patterson Companies (PDCO) after the company announced that it has signed a definitive agreement to be acquired by Patient Square Capital for $31.35 per share in cash. Despite current weakness in dental and companion animal health trends, the firm views the takeout valuation as “reasonable,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDCO:
- Patterson Companies price target raised to $31 from $25 at Baird
- M&A News: Patterson Companies Stock (PDCO) Rallies on Patient Square Deal
- Albertsons terminates Kroger deal, Macy’s reports Q3 beat: Morning Buzz
- Patterson Companies downgraded to Market Perform from Outperform at Leerink
- Patterson Companies to be acquired by Patient Square for $31.35 per share